SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-20-010091
Filing Date
2020-05-08
Accepted
2020-05-08 16:40:24
Documents
6
Period of Report
2020-05-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dffn20200507_8k.htm 8-K 30720
2 EXHIBIT 4.1 ex_185437.htm EX-4.1 110330
3 EXHIBIT 4.2 ex_185438.htm EX-4.2 110772
4 EXHIBIT 10.1 ex_185439.htm EX-10.1 32842
5 EXHIBIT 99.1 ex_185440.htm EX-99.1 15192
6 logo02.gif GRAPHIC 4839
  Complete submission text file 0001437749-20-010091.txt   308158
Mailing Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902
Business Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

IRS No.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37942 | Film No.: 20861224
SIC: 2834 Pharmaceutical Preparations